WINTON GROUP Ltd Acquires 1,006 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

WINTON GROUP Ltd boosted its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 43.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,343 shares of the company’s stock after acquiring an additional 1,006 shares during the quarter. WINTON GROUP Ltd’s holdings in Medpace were worth $1,111,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. R Squared Ltd purchased a new position in shares of Medpace in the 4th quarter worth approximately $30,000. SBI Securities Co. Ltd. purchased a new position in Medpace during the fourth quarter worth $31,000. Jones Financial Companies Lllp increased its position in Medpace by 2,750.0% during the fourth quarter. Jones Financial Companies Lllp now owns 114 shares of the company’s stock valued at $38,000 after acquiring an additional 110 shares during the last quarter. Lindbrook Capital LLC raised its stake in shares of Medpace by 27.6% in the fourth quarter. Lindbrook Capital LLC now owns 134 shares of the company’s stock valued at $45,000 after acquiring an additional 29 shares during the period. Finally, True Wealth Design LLC raised its stake in shares of Medpace by 16,800.0% in the third quarter. True Wealth Design LLC now owns 169 shares of the company’s stock valued at $56,000 after acquiring an additional 168 shares during the period. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Medpace Price Performance

NASDAQ:MEDP opened at $312.36 on Friday. The company has a 50-day moving average of $335.90 and a 200 day moving average of $339.07. Medpace Holdings, Inc. has a 1-year low of $302.01 and a 1-year high of $459.77. The firm has a market cap of $9.52 billion, a PE ratio of 24.73, a price-to-earnings-growth ratio of 3.81 and a beta of 1.47.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, beating analysts’ consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. Sell-side analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Analyst Ratings Changes

MEDP has been the topic of several analyst reports. Robert W. Baird upped their price target on shares of Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a report on Monday, January 27th. Leerink Partners started coverage on Medpace in a research note on Monday, March 24th. They set a “market perform” rating and a $330.00 target price on the stock. Finally, Leerink Partnrs raised Medpace to a “hold” rating in a research note on Monday, March 24th. Nine investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $376.30.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.